Geneva staff reluctantly accept modestly improved Merck Serono offer
This article was originally published in Scrip
The staff at Merck Serono's Geneva headquarters have ended their resistance to the company's plans to close the site and move its activities to parent company Merck KGaA's German headquarters and R&D sites elsewhere around the world (scripintelligence.com, 24 April 2012). Staff and Unia, the Swiss trade union representing them, have accepted a final package of severance terms from the company.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.